Press Releases.
- January 9, 2026 — Naveris to Highlight New Publications at the 44th Annual J.P. Morgan Healthcare Conference
- November 17, 2025 — Naveris Announces Expanded Medicare Coverage for the NavDx® Test in Identification of Molecular Residual Disease of Anal Squamous Cell Carcinoma
- January 10, 2025 — Naveris Announces Expansion of the NavDx® Test in Anal Cancer Molecular Residual Disease Surveillance
- October 9, 2024 — Naveris Announces Expanded Commercial Payor Coverage for NavDx Test from Blue Shield of California
- September 28, 2024 — Naveris to Showcase Advances in Precision Surveillance for HPV-Associated Oropharyngeal Cancer Using the NavDx® Test at the 2024 ASTRO Annual Meeting
- September 27, 2024 — Naveris Presents New Data on the NavDx® test for HPV-Associated Oropharyngeal Cancer at the 2024 AAO-HNS Annual Meeting
- June 27, 2024 — New Multicenter Study Highlights Use of the NavDx® Test in Resolving Clinically Indeterminate Findings
- May 29, 2024 — Naveris to Present New Data Highlighting Clinical Utility of the NavDx® Test at the 2024 ASCO Annual Meeting
- April 24, 2024 — Naveris Announces Launch of Phase II Clinical Study in MRD+ Head and Neck Cancer
- March 21, 2024 — Naveris Awarded ADLT Status by CMS for the NavDx® Test
- March 14, 2024 — Naveris Announces New Data at EUROGIN International Multidisciplinary HPV Congress 2024
- March 1, 2024 — Naveris Unveils NAVigate-HPV: A Groundbreaking Registry to Advance HPV-Driven Cancer Diagnosis and Treatment
- November 30, 2023 — Naveris Receives Medicare Coverage for NavDx® Test
- September 19, 2022 — Naveris, Inc. Raises $51 Million to Advance Commercialization of NavDx
- December 15, 2020 — Naveris, Inc. Raises $19 Million in Financing to Advance and Commercialize Blood Tests for Early Detection of HPV and Other Viral-Related Cancers